Updated:
Quebec Consortium for Drug Discovery
The Quebec Consortium for Drug Discovery was formed with provincial support from Quebec and Ontario to bridge lab research and clinical investment.
Quebec Consortium for Drug Discovery
The Quebec Consortium for Drug Discovery was formed with provincial support from Quebec and Ontario to bridge lab research and clinical investment. It is not a single family office but a consortium that coordinates government grants, academic institutions, and private investors to de-risk drug discovery projects. The consortium funds a portfolio of small-molecule and biologic candidates, typically at preclinical through Phase I stages. Disease areas include oncology, rare genetic disorders, and metabolic conditions. It operates across Quebec and Ontario, with anchor collaborations at universities in Montreal and Toronto. Named portfolio companies include spinouts from McGill University and the Université de Montréal. Deployment and staffing figures are not public. The consortium maintains a lean operational team, supplemented by academic principal investigators and industry partners. No philanthropic foundation or separate investment vehicle has been identified as affiliated. Recent activity is not documented in public sources. The consortium represents a structural experiment in regional drug development, blending public research funding with private sector governance. Its governance model involves a board composed of academic, government, and industry representatives — distinct from typical venture capital or corporate R&D structures.
General information
Firm type
Non-profit biopharmaceutical research consortium
Year founded
2008
Location
Region
North America
Country
Canada
City
Montreal
Corporate office
Montreal, Quebec, Canada
Additional offices
Toronto, Ontario, Canada
Principals
Diane Gosselin
founder
Véronique Dugas
operator
Carl Baillargeon
operator
Sector focus
Frequently asked questions
How does the consortium source proprietary deal flow?
Deal flow originates primarily from academic institutions in Quebec and Ontario, including McGill University and Université de Montréal. The consortium screens preclinical projects from these universities and provides funding to advance candidates toward clinical proof-of-concept. Proprietary access is driven by geographic proximity and academic partnerships.
Which disease areas does the consortium explicitly prioritize?
The consortium targets oncology, rare genetic disorders, and metabolic conditions. It focuses on small molecules and biologics. Specific disease subareas have not been publicly detailed, but the emphasis is on unmet medical needs and assets emanating from Quebec's academic research ecosystem.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: